Rakhi Maiwall1, Suman Kumar2, Shivendra Singh Chandel1, Guresh Kumar3, Archana Rastogi3, Chhagan Bihari3, Manoj Kumar Sharma1, Bhaskar Thakur4, K Jamwal1, Suman Nayak5, R P Mathur5, S K Sarin6. 1. Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), D1, Vasantkunj, New Delhi, 110070, India. 2. Department of Clinical Hematology, Command Hospital (Eastern Command), Kolkata, India. 3. Department of Biostatistics, Institute of Liver and Biliary Sciences, New Delhi, India. 4. Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India. 5. Department of Nephrology, Institute of Liver and Biliary Sciences, New Delhi, India. 6. Department of Hepatology, Institute of Liver and Biliary Sciences (ILBS), D1, Vasantkunj, New Delhi, 110070, India. shivsarin@gmail.com.
Abstract
BACKGROUND AND AIMS: The current definitions of acute kidney injury (AKI) including HRS have been derived from patients with decompensated cirrhosis. No studies have carefully addressed AKI in patients with acute on chronic liver failure (ACLF). We evaluated the prevalence, spectrum, natural history and mortality of AKI at admission and new-onset AKI in hospitalized patients with ACLF and compared the results with patients with acute decompensation of cirrhosis (ADC). PATIENTS AND METHODS: Consecutive patients with ACLF (n = 382) and ADC (n = 451) were prospectively studied. Serial renal and liver functions were recorded and correlated with the disease course and outcome. RESULTS: AKI at admission and new onset AKI in the hospital were not different in patients with ACLF and ADC (p > 0.05). However, a significant difference in the spectrum of AKI was noted; functional volume-responsive AKI was more common (p < 0.05) in ADC, while patients with ACLF more frequently had the structural form of AKI (p < 0.05). Moreover, patients with ADC had significantly less AKI progression (p < 0.05) and prolonged duration (p < 0.05), a lower requirement of RRT (p < 0.05) and also less AKI resolution (p < 0.05) compared to ACLF patients. Patients with ACLF (versus ADC) had a significantly higher mortality on multivariate analysis. CONCLUSIONS: The kidneys are differentially affected in patients with cirrhosis with or without liver failure. Patients with ACLF with AKI have more structural AKI, greater potential for reversibility despite higher progression as well as higher mortality compared to patients with ADC. Prevention and early detection of AKI should be considered in patients with ACLF.
BACKGROUND AND AIMS: The current definitions of acute kidney injury (AKI) including HRS have been derived from patients with decompensated cirrhosis. No studies have carefully addressed AKI in patients with acute on chronic liver failure (ACLF). We evaluated the prevalence, spectrum, natural history and mortality of AKI at admission and new-onset AKI in hospitalized patients with ACLF and compared the results with patients with acute decompensation of cirrhosis (ADC). PATIENTS AND METHODS: Consecutive patients with ACLF (n = 382) and ADC (n = 451) were prospectively studied. Serial renal and liver functions were recorded and correlated with the disease course and outcome. RESULTS: AKI at admission and new onset AKI in the hospital were not different in patients with ACLF and ADC (p > 0.05). However, a significant difference in the spectrum of AKI was noted; functional volume-responsive AKI was more common (p < 0.05) in ADC, while patients with ACLF more frequently had the structural form of AKI (p < 0.05). Moreover, patients with ADC had significantly less AKI progression (p < 0.05) and prolonged duration (p < 0.05), a lower requirement of RRT (p < 0.05) and also less AKI resolution (p < 0.05) compared to ACLF patients. Patients with ACLF (versus ADC) had a significantly higher mortality on multivariate analysis. CONCLUSIONS: The kidneys are differentially affected in patients with cirrhosis with or without liver failure. Patients with ACLF with AKI have more structural AKI, greater potential for reversibility despite higher progression as well as higher mortality compared to patients with ADC. Prevention and early detection of AKI should be considered in patients with ACLF.
Authors: Paolo Angeli; Pere Gines; Florence Wong; Mauro Bernardi; Thomas D Boyer; Alexander Gerbes; Richard Moreau; Rajiv Jalan; Shiv K Sarin; Salvatore Piano; Kevin Moore; Samuel S Lee; Francois Durand; Francesco Salerno; Paolo Caraceni; W Ray Kim; Vicente Arroyo; Guadalupe Garcia-Tsao Journal: Gut Date: 2015-01-28 Impact factor: 23.059
Authors: Justin M Belcher; Guadalupe Garcia-Tsao; Arun J Sanyal; Harjit Bhogal; Joseph K Lim; Naheed Ansari; Steven G Coca; Chirag R Parikh Journal: Hepatology Date: 2012-12-06 Impact factor: 17.425
Authors: Mark A Perazella; Steven G Coca; Mehmet Kanbay; Ursula C Brewster; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2008-09-10 Impact factor: 8.237
Authors: Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo Journal: Gastroenterology Date: 2013-03-06 Impact factor: 22.682
Authors: Justin M Belcher; Arun J Sanyal; Aldo J Peixoto; Mark A Perazella; Joseph Lim; Heather Thiessen-Philbrook; Naheed Ansari; Steven G Coca; Guadalupe Garcia-Tsao; Chirag R Parikh Journal: Hepatology Date: 2014-06-26 Impact factor: 17.425
Authors: Peter Fickert; Elisabeth Krones; Marion J Pollheimer; Andrea Thueringer; Tarek Moustafa; Dagmar Silbert; Emina Halilbasic; Min Yang; Hartmut Jaeschke; Geurt Stokman; Rebecca G Wells; Kathrin Eller; Alexander R Rosenkranz; Gosta Eggertsen; Carsten A Wagner; Cord Langner; Helmut Denk; Michael Trauner Journal: Hepatology Date: 2013-10-15 Impact factor: 17.425